Pfizer Inc said on Friday it has applied to U.S. health regulators for emergency use authorization (EUA) of its COVID-19 vaccine, a major step toward providing protection against the new coronavirus for pandemic-weary Americans.
The application to the U.S. Food and Drug Administration (FDA) comes just days after Pfizer and German partner BioNTech SE reported final trial results that showed the vaccine was 95 per cent effective in preventing COVID-19 with no major safety concerns.
Pfizer Inc said on Friday it has applied to U.S. health regulators for emergency use authorization (EUA) of its COVID-19 vaccine, a major step toward providing protection against the new coronavirus for pandemic-weary Americans.
The application to the U.S. Food and Drug Administration (FDA) comes just days after Pfizer and German partner BioNTech SE reported final trial results that showed the vaccine was 95 per cent effective in preventing COVID-19 with no major safety concerns.
Pfizer Inc said on Friday it has applied to U.S. health regulators for emergency use authorization (EUA) of its COVID-19 vaccine, a major step toward providing protection against the new coronavirus for pandemic-weary Americans.
The application to the U.S. Food and Drug Administration (FDA) comes just days after Pfizer and German partner BioNTech SE reported final trial results that showed the vaccine was 95 per cent effective in preventing COVID-19 with no major safety concerns.
comments